| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Muscle and Cell Physiology Laboratory, Department of Physiology, The University of Melbourne, Parkville, Victoria 3052, Australia
Received 26 March 1996; accepted in final form 18 September 1996.
Hayes, Alan, and David A. Williams. Contractile
properties of clenbuterol-treated mdx
muscle are enhanced by low-intensity swimming. J. Appl. Physiol. 82(2): 435-439, 1997.
The
2-agonist clenbuterol has
potent anabolic properties in normal and denervated muscle and, as
such, may be of use in muscle wasting diseases such as muscular
dystrophy. However, potential side effects such as the transformation
of the fiber type pool toward increased proportions of fast-twitch
fibers must be balanced with the beneficial anabolic properties. In the
present report, we clearly show that extensor digitorum longus and
soleus muscles from dystrophic mdx mice exposed to a combination of clenbuterol and low-intensity endurance swimming exercise did not undergo the slow- to fast-twitch fiber transformations caused by clenbuterol administration alone, yet
increases in the force-generating capacity of the soleus (30-40%) that resulted from the clenbuterol treatment were maintained after the
swimming program. The increased sensitivity of dystrophin-deficient dystrophic muscle to clenbuterol and low-intensity exercise that is
evident in this study may have therapeutic implications in the
treatment of muscle wasting diseases.
2-agonist; endurance
exercise; muscle fiber; muscular dystrophy
This article has been cited by other articles:
|
|
 |
|
  G. S. Lynch and J. G. Ryall Role of {beta}-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease Physiol Rev, April 1, 2008; 88(2): 729 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Skura, E. G. Fowler, G. T. Wetzel, M. Graves, and M. J. Spencer Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy Neurology, January 8, 2008; 70(2): 137 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.L. van der Kooi, O.J.M. Vogels, R.J.G.P. van Asseldonk, E. Lindeman, J.C.M. Hendriks, M. Wohlgemuth, S.M. van der Maarel, and G.W. Padberg Strength training and albuterol in facioscapulohumeral muscular dystrophy Neurology, August 24, 2004; 63(4): 702 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pellegrino, G. D'Antona, S. Bortolotto, F. Boschi, O. Pastoris, R. Bottinelli, B. Polla, and C. Reggiani Clenbuterol antagonizes glucocorticoid-induced atrophy and fibre type transformation in mice Exp Physiol, January 1, 2004; 89(1): 89 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Burniston, Y. Ng, W. A. Clark, J. Colyer, L.-B. Tan, and D. F. Goldspink Myotoxic effects of clenbuterol in the rat heart and soleus muscle J Appl Physiol, November 1, 2002; 93(5): 1824 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Kissel, M. P. McDermott, J. R. Mendell, W. M. King, S. Pandya, R. C. Griggs, and R. Tawil Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy Neurology, October 23, 2001; 57(8): 1434 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mokhtarian, J. P. Lefaucheur, P. C. Even, and A. Sebille Hindlimb immobilization applied to 21-day-old mdx mice prevents the occurrence of muscle degeneration J Appl Physiol, March 1, 1999; 86(3): 924 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hayes and D. A. Williams Contractile function and low-intensity exercise effects of old dystrophic (mdx) mice Am J Physiol Cell Physiol, April 1, 1998; 274(4): C1138 - C1144. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
